Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Should l Buy LCTX?
Source: Newsfilter
Company Presentation Announcement: Lineage Cell Therapeutics, Inc. will have its CEO Brian M. Culley present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at the Nasdaq headquarters in New York.
About Lineage's Innovations: The company focuses on developing allogeneic cell therapies for unmet medical needs, with a pipeline that includes therapies for retinal degeneration, spinal cord injuries, and auditory neuropathy, utilizing proprietary cell-based technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LCTX
Wall Street analysts forecast LCTX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.590
Low
3.00
Averages
4.50
High
9.00
Current: 1.590
Low
3.00
Averages
4.50
High
9.00
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Initiates Production of α-Klotho Cells
- Production Milestone: Avaí Bio has initiated the manufacturing of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to enhance the market potential for anti-aging therapies.
- Broad Market Outlook: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Innovation: The Cell-in-a-Box® technology protects transplanted cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing a critical challenge in cell therapy and enhancing treatment efficacy and safety.
- Dual-Program Strategy: Avaí Bio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, targeting enormous markets such as Alzheimer's disease, cardiovascular diseases, and kidney disease, demonstrating its strategic positioning in the biotechnology field.
See More
Avaí Bio Initiates α-Klotho Cell Production
- Manufacturing Milestone: Avaí Bio has initiated the production of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to accelerate the commercialization of anti-aging therapies.
- Massive Market Potential: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Advantage: The Cell-in-a-Box® technology protects therapeutic cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing the low survival rates of transplanted cells and enhancing the sustainability of treatment outcomes.
- Strategic Positioning: Avaí Bio's dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, with enormous addressable markets, as the Alzheimer's disease market alone is projected to reach $32.8 billion by 2033.
See More
Major Wall Street Rating Changes on Wednesday
- Starbucks Downgrade: RBC downgraded Starbucks from Outperform to Sector Perform, citing a slower-than-expected turnaround in the U.S. business, which has not yielded the anticipated small investments, making it difficult to justify an Outperform rating and negatively impacting stock performance.
- NRG Energy Upgrade: Wolfe upgraded NRG Energy from Peer Perform to Outperform, highlighting its strong positioning as a data center beneficiary with over 6 GW of gas new build potential, which enhances the company's diversification and long-term power generation capabilities.
- Block Stock Outlook: Truist upgraded Block from Hold to Buy, noting that after a ~40% reduction in workforce, the stock has significantly de-rated, and improving free cash flow could lead to unexpected capital returns, boosting market confidence.
- Netflix Reinstatement: Citi reinstated Netflix as Buy, forecasting an increase in FY26 EBIT guidance and a U.S. price hike in Q4 2026, with these catalysts expected to drive a stock price increase of 5% to 17%.
See More
Lineage Cell Therapeutics Q4 2025 Earnings Call Insights
- Extended Cash Runway: Lineage has extended its cash runway to Q2 2028 through recent warrant exercises, which is expected to support planned operations and reflects positive progress in financial management.
- Clinical Research Expansion: The GAlette study has added 10 new clinical sites, significantly up from 8 in the previous 6 months, indicating the company's proactive stance in clinical trial preparations that could facilitate later-stage trials.
- Revenue Growth: Total revenues for Q4 2025 reached $6.6 million, an increase of $3.7 million compared to Q4 2024, primarily driven by higher collaboration revenue from the Roche agreement, showcasing success in partnership development.
- Increased R&D Spending: R&D expenses for the fourth quarter totaled $8.2 million, up $4.8 million year-over-year, demonstrating the company's ongoing investment in technology development, despite an overall net loss of $63.5 million largely due to non-cash charges.
See More
Lineage Cell Therapeutics Q4 Earnings Announcement Scheduled
- Earnings Announcement Date: Lineage Cell Therapeutics is set to announce its Q4 earnings on March 5th after market close, with investors keenly awaiting the latest financial performance to assess future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.04, indicating challenges in profitability that could impact investor confidence and stock performance.
- Revenue Projections: Revenue is expected to be $1.96 million, reflecting a significant year-over-year decline of 32.4%, which highlights competitive pressures and weakened product demand, potentially affecting future liquidity.
- Historical Performance: Over the past two years, LCTX has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, demonstrating relative stability in financial forecasting, which may provide some reassurance to investors.
See More
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
See More
Avaí Bio Initiates Production of α-Klotho Cells
- Production Milestone: Avaí Bio has initiated the manufacturing of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to enhance the market potential for anti-aging therapies.
- Broad Market Outlook: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Innovation: The Cell-in-a-Box® technology protects transplanted cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing a critical challenge in cell therapy and enhancing treatment efficacy and safety.
- Dual-Program Strategy: Avaí Bio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, targeting enormous markets such as Alzheimer's disease, cardiovascular diseases, and kidney disease, demonstrating its strategic positioning in the biotechnology field.
See More
Avaí Bio Initiates α-Klotho Cell Production
- Manufacturing Milestone: Avaí Bio has initiated the production of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to accelerate the commercialization of anti-aging therapies.
- Massive Market Potential: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Advantage: The Cell-in-a-Box® technology protects therapeutic cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing the low survival rates of transplanted cells and enhancing the sustainability of treatment outcomes.
- Strategic Positioning: Avaí Bio's dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, with enormous addressable markets, as the Alzheimer's disease market alone is projected to reach $32.8 billion by 2033.
See More
Major Wall Street Rating Changes on Wednesday
- Starbucks Downgrade: RBC downgraded Starbucks from Outperform to Sector Perform, citing a slower-than-expected turnaround in the U.S. business, which has not yielded the anticipated small investments, making it difficult to justify an Outperform rating and negatively impacting stock performance.
- NRG Energy Upgrade: Wolfe upgraded NRG Energy from Peer Perform to Outperform, highlighting its strong positioning as a data center beneficiary with over 6 GW of gas new build potential, which enhances the company's diversification and long-term power generation capabilities.
- Block Stock Outlook: Truist upgraded Block from Hold to Buy, noting that after a ~40% reduction in workforce, the stock has significantly de-rated, and improving free cash flow could lead to unexpected capital returns, boosting market confidence.
- Netflix Reinstatement: Citi reinstated Netflix as Buy, forecasting an increase in FY26 EBIT guidance and a U.S. price hike in Q4 2026, with these catalysts expected to drive a stock price increase of 5% to 17%.
See More
Lineage Cell Therapeutics Q4 2025 Earnings Call Insights
- Extended Cash Runway: Lineage has extended its cash runway to Q2 2028 through recent warrant exercises, which is expected to support planned operations and reflects positive progress in financial management.
- Clinical Research Expansion: The GAlette study has added 10 new clinical sites, significantly up from 8 in the previous 6 months, indicating the company's proactive stance in clinical trial preparations that could facilitate later-stage trials.
- Revenue Growth: Total revenues for Q4 2025 reached $6.6 million, an increase of $3.7 million compared to Q4 2024, primarily driven by higher collaboration revenue from the Roche agreement, showcasing success in partnership development.
- Increased R&D Spending: R&D expenses for the fourth quarter totaled $8.2 million, up $4.8 million year-over-year, demonstrating the company's ongoing investment in technology development, despite an overall net loss of $63.5 million largely due to non-cash charges.
See More
Lineage Cell Therapeutics Q4 Earnings Announcement Scheduled
- Earnings Announcement Date: Lineage Cell Therapeutics is set to announce its Q4 earnings on March 5th after market close, with investors keenly awaiting the latest financial performance to assess future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.04, indicating challenges in profitability that could impact investor confidence and stock performance.
- Revenue Projections: Revenue is expected to be $1.96 million, reflecting a significant year-over-year decline of 32.4%, which highlights competitive pressures and weakened product demand, potentially affecting future liquidity.
- Historical Performance: Over the past two years, LCTX has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, demonstrating relative stability in financial forecasting, which may provide some reassurance to investors.
See More
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
See More
